Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether).

[1]  B. Vargaftig,et al.  Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. , 1982, Thrombosis research.

[2]  B. Vargaftig,et al.  Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. , 1981, European journal of pharmacology.

[3]  M. Bristow,et al.  Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[4]  T. Williams,et al.  Control of vascular permeability by polymorphonuclear leukocytes in inflammation , 1981, Nature.

[5]  B. Vargaftig,et al.  Present concepts on the mechanisms of platelet aggregation. , 1981, Biochemical pharmacology.

[6]  B. Vargaftig,et al.  Is Phospholipase A2 (PLA2) Involved In PAF-Acether Formation By Platelets , 1981 .

[7]  B. Vargaftig,et al.  Role of the metabolites of arachidonate in platelet-dependent and independent experimental bronchoconstriction. , 1981, Bulletin europeen de physiopathologie respiratoire.

[8]  P. Moore,et al.  Human plasma contains prostaglandin 'reciprocal coupling factor'. , 1980, European journal of pharmacology.

[9]  B. Vargaftig,et al.  Activation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. , 1980, European journal of pharmacology.

[10]  B. Vargaftig,et al.  Platelet‐Activating Factor (PAF‐Acether) Secretion from Platelets: Effect of Aggregating Agents , 1980, British journal of haematology.

[11]  B. Vargaftig,et al.  Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. , 1980, European journal of pharmacology.

[12]  B. Vargaftig,et al.  L8027 and 1-nonyl-imidazole as non-selective inhibitors of thromboxane synthesis. , 1979, European journal of pharmacology.

[13]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[14]  B. Vargaftig,et al.  Mechanisms of bronchoconstriction and of thrombocytopenia induced by collagen in the guinea pig. , 1979, European journal of pharmacology.

[15]  J. Cazenave,et al.  Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[16]  B. Vargaftig,et al.  The role of platelet-activating factor in platelet aggregation , 1979, Nature.

[17]  J. Polonsky,et al.  Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. , 1979 .

[18]  H. Weiss,et al.  Secretable storage pools in platelets. , 1979, Annual review of medicine.

[19]  B. Vargaftig,et al.  ROLE OF PLATELETS IN ASPIRIN‐SENSITIVE BRONCHOCONSTRICTION IN THE GUINEA‐PIG; INTERACTIONS WITH SALICYLIC ACID , 1978, British journal of pharmacology.

[20]  J. Cazenave,et al.  Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187. , 1977, The Journal of laboratory and clinical medicine.

[21]  B. Vargaftig.  Carrageenan and thrombin trigger prostaglandin synthetase‐independent aggregation of rabbit platelets: inhibition by phospholipase A2 inhibitors * , 1977, The Journal of pharmacy and pharmacology.

[22]  B. Vargaftig,et al.  Acute hypotension due to carrageenan, arachidonic acid and slow reacting substance C in the rabbit: role of platelets and nature of pharmacological antagonism. , 1977, European journal of pharmacology.

[23]  Vargaftig Bb.  Involvement of mediators in the interaction of platelets and carrageenan. , 1977 .

[24]  Classen Hg,et al.  Platelet aggregation induced by anaphylatoxin and its inhibition. , 1975 .

[25]  D. Ross,et al.  Morphine and Ethanol: Selective Depletion of Regional Brain Calcium , 1974, Science.

[26]  B. Vargaftig,et al.  Selective inhibition by mepacrine of the release of “rabbit aorta contracting substance” evoked by the administration of bradykinin , 1972, The Journal of pharmacy and pharmacology.

[27]  D. Branch,et al.  Wavelength Shifts of Intensity Minima in Type I Supernova Spectra , 1971 .

[28]  B. Vargaftig,et al.  Release of vasoactive substances from guinea-pig lungs by slow-reacting substance c and arachidonic acid. Its blockade by nonsteroid anti-inflammatory agents. , 1971, Pharmacology.

[29]  C. Sadavongvivad.  Pharmacological significance of biogenic amines in the lungs: 5‐hydroxytryptamine , 1970, British journal of pharmacology.

[30]  D. Aviado,et al.  Pharmacological significance of biogenic amines in the lungs: histamine , 1970, British journal of pharmacology.

[31]  J. Vane,et al.  Release of Additional Factors in Anaphylaxis and its Antagonism by Anti-inflammatory Drugs , 1969, Nature.